Why these mistakes matter
This page covers AI products for clinicians, providers, patients and life sciences.
Most rounds do not fail on one big problem. They stall because an investor finds something the founder should have fixed or explained earlier, and confidence drops. Each mistake below says why it happens, how investors tend to react and what to do instead.
Mistake 1: Optimistic approval dates
Why it happens: Founders plan to the best case to keep the raise small.
How investors react: Investors expect delays and worry the round will run out first.
What to do instead: Plan with contingency for regulatory delay and raise enough to survive it.
Mistake 2: Claims that change your classification
Why it happens: Sales copy promises diagnosis or treatment benefits.
How investors react: Investors see hidden regulatory risk and possible rework.
What to do instead: Write a careful intended purpose statement and keep marketing consistent with it.
Mistake 3: Assuming the product is not a medical device
Why it happens: Software feels different from hardware.
How investors react: Diligence teams check, and a wrong assumption is costly.
What to do instead: Take advice on classification early and record the reasoning.
Mistake 4: Innovation-budget pilots with no buyer
Why it happens: Innovation teams fund trials easily.
How investors react: Investors ask who pays at scale and from which budget.
What to do instead: Identify the recurring budget holder before counting a pilot as traction.
Mistake 5: Relying on retrospective accuracy alone
Why it happens: Historical data is easy to test on.
How investors react: Investors want evidence of performance in real settings.
What to do instead: Cost an evidence plan that moves from validation to real-world use.
Mistake 6: Short-term data access
Why it happens: Data agreements were signed for a single project.
How investors react: Unclear ongoing rights weaken the whole product.
What to do instead: Secure lasting data rights with a clear lawful basis.
Mistakes every sector shares
Alongside the sector-specific points, these general errors come up in almost every round:
- Raising without a clear milestone the money is meant to reach.
- A messy cap table or missing IP assignments found late in diligence.
- Pitching investors who do not back your sector or stage.
- Starting to raise with too little runway left to negotiate calmly.
Healthtech: common mistake versus better approach
| Mistake | Better approach |
|---|---|
| Optimistic approval dates | Plan with contingency for regulatory delay and raise enough to survive it. |
| Claims that change your classification | Write a careful intended purpose statement and keep marketing consistent with it. |
| Assuming the product is not a medical device | Take advice on classification early and record the reasoning. |
| Innovation-budget pilots with no buyer | Identify the recurring budget holder before counting a pilot as traction. |
| Relying on retrospective accuracy alone | Cost an evidence plan that moves from validation to real-world use. |
| Short-term data access | Secure lasting data rights with a clear lawful basis. |
Questions to prepare before you pitch
- Does our marketing match our intended purpose?
- How long could approval slip before we run out of money?
- Who pays for this at scale?
- Do we have lasting rights to our training data?
How KJ Enterprises evaluates healthtech businesses
KJ Enterprises considers healthtech businesses with a realistic regulatory plan, contingency for delay and a genuine recurring buyer.
If that describes your company, you can apply for investment. Related reading: the complete funding guide and the step-by-step how-to and costs and terms and the readiness checklist and machine learning mistakes to avoid.